Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 90

1.

Mast cells and eosinophils in invasive breast carcinoma.

Amini RM, Aaltonen K, Nevanlinna H, Carvalho R, Salonen L, Heikkilä P, Blomqvist C.

BMC Cancer. 2007 Aug 29;7:165.

2.

The presence of stromal mast cells identifies a subset of invasive breast cancers with a favorable prognosis.

Dabiri S, Huntsman D, Makretsov N, Cheang M, Gilks B, Bajdik C, Gelmon K, Chia S, Hayes M.

Mod Pathol. 2004 Jun;17(6):690-5. Erratum in: Mod Pathol. 2004 Aug;17(8):1025. Badjik, Chris [corrected to Bajdik, Chris].

3.

Mast cells in invasive ductal breast cancer: different behavior in high and minimum hormone-receptive cancers.

della Rovere F, Granata A, Familiari D, D'Arrigo G, Mondello B, Basile G.

Anticancer Res. 2007 Jul-Aug;27(4B):2465-71.

4.

Immunohistochemical localisation of tenascin in invasive ductal carcinoma of the breast.

Tökés AM, Hortoványi E, Csordás G, Kulka J, Mózes G, Hatalyák A, Kádár A.

Anticancer Res. 1999 Jan-Feb;19(1A):175-9.

PMID:
10226540
5.

Breast carcinoma in women 35 years and younger: a pathological study.

Fernandopulle SM, Cher-Siangang P, Tan PH.

Pathology. 2006 Jun;38(3):219-22.

PMID:
16753742
7.

Mast cells in breast cancer.

Aaltomaa S, Lipponen P, Papinaho S, Kosma VM.

Anticancer Res. 1993 May-Jun;13(3):785-8.

PMID:
8317912
8.

Is there 'progression through grade' in ductal invasive breast cancer?

Schymik B, Buerger H, Krämer A, Voss U, van der Groep P, Meinerz W, van Diest PJ, Korsching E.

Breast Cancer Res Treat. 2012 Oct;135(3):693-703. doi: 10.1007/s10549-012-2195-1. Epub 2012 Aug 12.

PMID:
22886478
9.

[Proliferation index and its prognostic value in invasive ductal breast carcinoma].

Falco M.

Ann Acad Med Stetin. 2009;55(1):22-30. Polish.

PMID:
20349588
12.

Distribution and significance of nerve growth factor receptor (NGFR/p75NTR) in normal, benign and malignant breast tissue.

Reis-Filho JS, Steele D, Di Palma S, Jones RL, Savage K, James M, Milanezi F, Schmitt FC, Ashworth A.

Mod Pathol. 2006 Feb;19(2):307-19.

13.

The expression pattern of MUC1 (EMA) is related to tumour characteristics and clinical outcome of invasive ductal breast carcinoma.

van der Vegt B, de Roos MA, Peterse JL, Patriarca C, Hilkens J, de Bock GH, Wesseling J.

Histopathology. 2007 Sep;51(3):322-35. Epub 2007 Jul 23.

PMID:
17645748
14.

The value of COX-2 expression in the prognostic parameters of invasive ductal carcinoma of the breast.

Barısık NO, Keser SH, Gul AE, Sensu S, Kandemir NO, Kucuk HF, Gumus M, Karadayı N.

Med Oncol. 2011 Sep;28(3):703-8. doi: 10.1007/s12032-010-9503-6. Epub 2010 Mar 31.

PMID:
20354817
15.

Stromal CD10 expression in invasive breast carcinoma correlates with poor prognosis, estrogen receptor negativity, and high grade.

Makretsov NA, Hayes M, Carter BA, Dabiri S, Gilks CB, Huntsman DG.

Mod Pathol. 2007 Jan;20(1):84-9. Epub 2006 Nov 24.

17.

Microinvasive ductal carcinoma (T1mic) of the breast. The clinicopathological profile and immunohistochemical features of 28 cases.

Yang M, Moriya T, Oguma M, De La Cruz C, Endoh M, Ishida T, Hirakawa H, Orita Y, Ohuchi N, Sasano H.

Pathol Int. 2003 Jul;53(7):422-8.

PMID:
12828606
18.

Relationship of DNA ploidy to hormone receptor status and proliferation in invasive breast carcinoma.

Spiethoff A, Schenck A, Bohrer M.

J Cancer Res Clin Oncol. 2000 Dec;126(12):707-10.

PMID:
11153143
19.

Prognostic variables in invasive breast cancer: contribution of comedo versus noncomedo in situ component.

Brower ST, Ahmed S, Tartter PI, Bleiweiss I, Amberson JB.

Ann Surg Oncol. 1995 Sep;2(5):440-4.

PMID:
7496840
20.

Expression of amphiregulin and epidermal growth factor receptor in human breast cancer: analysis of autocriny and stromal-epithelial interactions.

Ma L, de Roquancourt A, Bertheau P, Chevret S, Millot G, Sastre-Garau X, Espié M, Marty M, Janin A, Calvo F.

J Pathol. 2001 Aug;194(4):413-9.

PMID:
11523048

Supplemental Content

Support Center